Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fibromun by Philogen for Leiomyosarcoma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...
Fibromun by Philogen for Soft Tissue Sarcoma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase III for Soft Tissue Sarcoma. According to GlobalData, Phase...
Fibromun by Philogen for Malignant Glioma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase II for Malignant Glioma. According to GlobalData, Phase II...
Fibromun by Philogen for Glioblastoma Multiforme (GBM): Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Fibromun by Philogen for Melanoma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
Fibromun by Philogen for Metastatic Melanoma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Fibromun by Philogen for Malignant Glioma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase II for Malignant Glioma. According to GlobalData, Phase II...
Fibromun by Philogen for Glioblastoma Multiforme (GBM): Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Fibromun by Philogen for Melanoma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
Risk adjusted net present value: What is the current valuation of Philogen's Fibromun?
Fibromun is a fusion protein commercialized by Philogen, with a leading Phase III program in Soft Tissue Sarcoma. According to...
Fibromun by Philogen for Liposarcoma: Likelihood of Approval
Fibromun is under clinical development by Philogen and currently in Phase III for Liposarcoma. According to GlobalData, Phase III drugs...